BioLineRx BLRX
NASDAQ BLRX
$2.21 +0.23 (+12.40%)
As of: Oct 20, 2026 · 2:30 PM EDT

BioLineRx (BLRX) Share-based Compensation (IS) (2010 - 2011)

Updated

Analysis

BioLineRx (BLRX) Share-based Compensation (IS) (2010 - 2011) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Stock Comp. (Qtr)
1 Eli Lilly 1,146.94 Bn 1,115.53 Bn 19.71 Bn -
2 Johnson & Johnson 624.96 Bn 543.49 Bn 17.26 Bn -
3 AbbVie 510.15 Bn 483.27 Bn 12.70 Bn -
4 Merck 366.13 Bn 320.51 Bn 12.21 Bn -
5 Novartis Ag 297.75 Bn 261.74 Bn 11.24 Bn -
6 Astrazeneca 261.93 Bn 235.62 Bn 12.86 Bn -
7 Amgen 236.51 Bn 191.91 Bn 7.24 Bn -
8 Gilead Sciences 194.27 Bn 168.47 Bn 6.22 Bn -
9 Pfizer 171.74 Bn 118.39 Bn 10.94 Bn -
10 BioLineRx 9.10 Mn -67.42 Mn 235,000.00 -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2011 110,071.75
Jun 30, 2010 142,141.03
API Access

BioLineRx Share-based Compensation (IS) API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=share-based-compensation-is&ticker=BLRX&period=max&api_key=YOUR_API_KEY